Atossa Therapeutics, Inc. (ATOS)Healthcare | Biotechnology | Seattle, United States | NasdaqCM
5.83 USD
+0.06
(1.040%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.70 -0.13 (-0.130%) ⇩ (April 17, 2026, 7:30 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:27 p.m. EDT
Analyst consensus shows a massive discrepancy between the aggressive 'Strong Buy' sentiment (Target mean $23 vs current ~$6) and the statistical forecast predicting a -18.8% downtrend. This suggests the catalyst is priced in or is about to expire. The short-term momentum is weakish (down 43% from 200-day avg), while long-term fundamentals are broken (negative earnings, cash burn, no dividends). This is a volatile event-driven spec vehicle with asymmetric risk, not a rational investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.608117 |
| AutoARIMA | 0.705447 |
| AutoETS | 0.705448 |
| MSTL | 0.707211 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 62% |
| H-stat | 0.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | 1.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 50,204,632 |
| Forward P/E | -2.34 |
| Beta | 1.35 |
| Website | https://www.atossatherapeutics.com |
As of April 18, 2026, 11:27 p.m. EDT: Options flow indicates a significant divergence between price action and open interest. Heavy put volume (2.8k contracts) and open interest at deep out-of-the-money strikes ($0.50, $1.00) for the April 17 expiry suggest a 'Gamma Squeeze' risk or a flight-to-safety position as price approaches ATM. This is contrasted by new call volume at $2.00 ATM levels, creating a mixed signal where participants are positioning for high volatility (long strangle potential) rather than a clear directional bull case. Long-dated (July/Oct) open interest is heavily skewed to out-of-the-money strikes ($7, $9), indicating speculators view this as a binary event-driven bet (clinical trial results) rather than a value play, with elevated IV (0.88-1.03) pricing in significant moves in either direction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.39270836 |
| Address1 | 107 Spring Street |
| All Time High | 33,480.0 |
| All Time Low | 3.76 |
| Ask | 7.28 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 58,180 |
| Average Daily Volume3 Month | 124,591 |
| Average Volume | 124,591 |
| Average Volume10Days | 58,180 |
| Beta | 1.345 |
| Bid | 4.16 |
| Bid Size | 2 |
| Book Value | 4.57 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.83 |
| Current Ratio | 5.526 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.9383 |
| Day Low | 5.665 |
| Display Name | Atossa Therapeutics |
| Dividend Date | 1,524,182,400 |
| Earnings Call Timestamp End | 1,742,905,800 |
| Earnings Call Timestamp Start | 1,742,905,800 |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda | -37,125,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.24 |
| Enterprise Value | 8,905,235 |
| Eps Current Year | -4.575 |
| Eps Forward | -2.495 |
| Eps Trailing Twelve Months | -4.04 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 206 902 9658 |
| Fifty Day Average | 4.8778 |
| Fifty Day Average Change | 0.95219994 |
| Fifty Day Average Change Percent | 0.19521095 |
| Fifty Two Week Change Percent | -39.270836 |
| Fifty Two Week High | 19.35 |
| Fifty Two Week High Change | -13.52 |
| Fifty Two Week High Change Percent | -0.698708 |
| Fifty Two Week Low | 3.76 |
| Fifty Two Week Low Change | 2.07 |
| Fifty Two Week Low Change Percent | 0.5505319 |
| Fifty Two Week Range | 3.76 - 19.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,385,000,000 |
| Float Shares | 8,607,314 |
| Forward Eps | -2.495 |
| Forward P E | -2.3366735 |
| Free Cashflow | -18,232,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00827 |
| Held Percent Institutions | 0.21436001 |
| Implied Shares Outstanding | 8,611,429 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,769,990,400 |
| Last Split Factor | 1:15 |
| Long Business Summary | Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. |
| Long Name | Atossa Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 50,204,632 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_100256926 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -34,770,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 50,893,143 |
| Number Of Analyst Opinions | 3 |
| Open | 5.81 |
| Operating Cashflow | -29,762,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 206 588 0256 |
| Post Market Change | -0.13000011 |
| Post Market Change Percent | -2.2298477 |
| Post Market Price | 5.7 |
| Post Market Time | 1,776,468,632 |
| Previous Close | 5.77 |
| Price Eps Current Year | -1.274317 |
| Price Hint | 2 |
| Price To Book | 1.275711 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.003 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.0599999 |
| Regular Market Change Percent | 1.03986 |
| Regular Market Day High | 5.9383 |
| Regular Market Day Low | 5.665 |
| Regular Market Day Range | 5.665 - 5.9383 |
| Regular Market Open | 5.81 |
| Regular Market Previous Close | 5.77 |
| Regular Market Price | 5.83 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 54,674 |
| Return On Assets | -0.37425 |
| Return On Equity | -0.62745 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,611,361 |
| Shares Percent Shares Out | 0.0381 |
| Shares Short | 327,683 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 361,039 |
| Short Name | Atossa Therapeutics, Inc. |
| Short Percent Of Float | 0.0381 |
| Short Ratio | 3.84 |
| Source Interval | 15 |
| State | WA |
| Symbol | ATOS |
| Target High Price | 25.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 23.0 |
| Target Median Price | 24.0 |
| Total Cash | 41,299,000 |
| Total Cash Per Share | 4.796 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.18525 |
| Two Hundred Day Average Change | -4.3552504 |
| Two Hundred Day Average Change Percent | -0.42760366 |
| Type Disp | Equity |
| Volume | 54,674 |
| Website | https://www.atossatherapeutics.com |
| Zip | 98,104 |